Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
Internal Medicine Journal|June 20, 2017
Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapseAndrew B M Lim, Cameron Curley, Chun Y Fong, et al.
Cancer Epidemiology|September 4, 2022
Associations between early-life growth pattern and body size and follicular lymphoma risk and survival: a family-based case-control studyMichael K Odutola, Marina T van Leeuwen, Jennifer Turner, et al.
The Lancet. Haematology|December 22, 2015
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trialHarry J Iland, Marnie Collins, Ken Bradstock, et al.
Occupational and Environmental Medicine|September 18, 2023
Occupational exposure to extremely low-frequency magnetic fields and follicular lymphoma risk: a family case-control studyMichael K Odutola, Marina T van Leeuwen, Fiona J Bruinsma, et al.
Frontiers in Nutrition|January 23, 2023
Dietary intake of animal-based products and likelihood of follicular lymphoma and survival: A population-based family case-control studyMichael K Odutola, Marina T van Leeuwen, Julie K Bassett, et al.
Haematologica|February 2, 2017
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14Mark Hertzberg, Maher K Gandhi, Judith Trotman, et al.
Blood|September 5, 2008
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapyTimothy P Hughes, Susan Branford, Deborah L White, et al.
Blood|December 19, 2014
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsDavid T Yeung, Michael P Osborn, Deborah L White, et al.
Blood Advances|April 9, 2020
LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphomaColm Keane, Soi C Law, Clare Gould, et al.
Blood|April 19, 2015
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencingDavid M Kurtz, Michael R Green, Scott V Bratman, et al.
Pageof 9